Cell Kinetics in Cervical Tumours Using Bromodeoxyuridine
Author Information
Author(s): B.S. Bolger, T.G. Cooke, R.P. Symonds, A.B. MacLean, P.D. Stanton
Primary Institution: University Department of Surgery, Glasgow Royal Infirmary
Hypothesis
Can the pre-treatment cell kinetics of cervical tumours be effectively measured using bromodeoxyuridine?
Conclusion
The study found significant intra-tumour heterogeneity in cell kinetics of cervical tumours, with a notable elevation in the labelling index in advanced stage and larger tumours.
Supporting Evidence
- 89% of tumours showed measurable cell kinetics.
- Significant elevation in labelling index was found in advanced stage tumours.
- Median S-phase duration was 12.1 hours.
- Median labelling index was 9.5%.
- Potential tumour doubling time was 4.4 days.
Takeaway
This study looked at how fast cervical cancer cells grow and found that there are big differences in growth rates within the same tumour.
Methodology
The study involved administering bromodeoxyuridine to patients and analyzing multiple biopsies from cervical tumours to measure cell kinetics.
Potential Biases
There is a risk of bias in the calculated labelling index due to the presence of normal cells in diploid tumour samples.
Limitations
The study had limitations in accurately measuring S-phase duration in some aneuploid tumours due to overlapping cell populations.
Participant Demographics
Patients with cervical carcinoma scheduled for staging or radical hysterectomy.
Statistical Information
P-Value
0.0001
Confidence Interval
95% C.I. - 1.9 to 3.6 for Ts, 5.0 to 12.1 for CLI, 17.0 to 39.2 for Tpot
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website